Why? I've previously gone through the JPMorgan presentation and watched the educational video. I like what I know about the Anavex molecules (I've also read Mayo's website, for that matter), and I like that Missling says the endpoints were met; but it is very, very weird, or amateurish, to state you've met the endpoints yet omit significant parts of the support for that statement that virtually every unbiased, knowledgeable investor and clinical trial expert expects to be included.
News 
Market Data 
Discover 
